Drug repurposing in autosomal dominant polycystic kidney disease: back to the future with pioglitazone

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited cause of end-stage kidney failure. At present, only one drug, tolvaptan, has been approved for use to slow disease progression, but its use is limited by reduced tolerability and idiosyncratic liver toxicity. Thiazolid...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Zhiguo, Valluru, Manoj K, Ong, Albert C M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Editorial Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243263/
https://www.ncbi.nlm.nih.gov/pubmed/34221378
http://dx.doi.org/10.1093/ckj/sfab062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243263/
https://www.ncbi.nlm.nih.gov/pubmed/34221378
http://dx.doi.org/10.1093/ckj/sfab062

Ejemplares similares